GlaxoSmithKline news from FierceVaccines
NewsCervarix data demonstrates prolonged protection
GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of cervical Read more...
GSK bird flu vaccine provides more positive data
New trial data on GlaxoSmithKline's experimental bird flu vaccine indicates that the drug works against a variety of subsets of the virus. A trial that recruited volunteers in Hong Kong, Taiwan, Read more...
GSK's secret vaccine adjuvant draws attention
GlaxoSmithKline's success advancing two pandemic vaccines--Prepandrix and Pandemrix--relies on a secret formula that drives efficacy of a low antigen dose in these adjuvated products. According to Read more...
| Press ReleasesGlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... PRESS RELEASE: GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breas GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases Data on abstract 6076 embargoed until Sunday 16 December Read more... PRESS RELEASE: GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay PHILADELPHIA, Dec. 17 -- GlaxoSmithKline announced today that it has received a complete response letter Read more... |
Get more GlaxoSmithKline coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight